SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

TAK-448

Cat. No.: HY-P0076

CAS No.: 1234319-68-6

Molecular Formula: $C_{58}H_{80}N_{16}O_{14}$

Molecular Weight: 1225.36

Sequence Shortening: Ac-{d-Tyr}-{Hyp}-NTF-{Aza-Gly}-L-{Arg(Me)}-W-NH2

Target: Kisspeptin Receptor

Pathway: GPCR/G Protein

Storage: Sealed storage, away from moisture

Powder -80°C 2 years

-20°C 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro

H_2O : 100 mg/mL (81.61 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.8161 mL	4.0804 mL	8.1609 mL
	5 mM	0.1632 mL	0.8161 mL	1.6322 mL
	10 mM	0.0816 mL	0.4080 mL	0.8161 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

TAK-448 (MVT-602) is a potent and full KISS1R agonist with an IC_{50} of 460 pM and an EC_{50} of 632 pM[1].

IC_{50} & Target

IC50: 460 pM (KISS1R)[1]

EC50: 632 pM (KISS1R)[1]

In Vivo

TAK-448 (0.01-3 mg/kg; given i.h.; dosings on day 0 and 28) has greater anti-tumor effects in VCaP xenograft model[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Rat VCaP xenograft androgen-sensitive prostate cancer model (7-week-old rats)
Dosage:	0.01, 0.03, 0.3, 3 mg/kg
Administration:	Given i.h.; dosings on day 0 and 28

Result:	Had greater anti-tumor effects in VCaP xenograft model.

REFERENCES

[1]. 1.Nishizawa N, et al. Design and Synthesis of an Investigational Nonapeptide KISS1 Receptor (KISS1R) Agonist, Ac-d-Tyr-Hydroxyproline (Hyp)-Asn-Thr-Phe-azaGly-Leu-Arg(Me)-Trp-NH2 (TAK-448), with Highly PotentTestosterone-Suppressive Activity and Excellent Water Solubility. J Med Chem. 2016 Oct 13;59(19):8804-8811.

[2]. Ishikawa K,et al. Usefulness of pharmacokinetic/efficacy analysis of an investigational kisspeptin analog, TAK-448, in quantitatively evaluating anti-tumor growth effect in the rat VCaP androgen-sensitiveprostate cancer model. Eur J Pharmacol. 2018 Jun 5;828:126-134.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA